Current FDA-approved treatments for ischemic stroke are either pharmacological (i.e., recombinant tissue plasminogen activator (r-tPA; alteplase)) or mechanical/surgical (i.e., endovascular thrombectomy (EVT)). This evidence concerns the gene PLAT and ischemic stroke.